Linhares Y, Freytes CO, Cherry M, et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL. Blood Adv. 2024;8(23):6114-6126.

Page 6119: In Table 2, under “Total (N = 82),” the any-grade percentages for constipation, decreased appetite, and diarrhea should be 23, not 24.